Eastern Cooperative Oncology Group Performance Status

Biomarker

Related News

10-Year Survival Similar With Chemoradiation or Surgery in Resectable Advanced NSCLC

Apr 09, 2026

Ten-year follow-up of the phase 3 ESPATUE trial found similar overall and progression-free survival with chemoradiotherapy boost or surgery in resectable advanced NSCLC after induction therapy.

Amivantamab Shows Promise in Adenoid Cystic Carcinoma and Head and Neck Cancer Trials

Feb 27, 2026

Phase 2 trial of amivantamab in recurrent/metastatic adenoid cystic carcinoma achieved 72.2% clinical benefit rate with good tolerability. Combination therapy with pembrolizumab is being evaluated in head and neck squamous cell cancer.